HUE054159T2 - HPK1 gátlók és azok alkalmazási módja - Google Patents

HPK1 gátlók és azok alkalmazási módja

Info

Publication number
HUE054159T2
HUE054159T2 HUE16813437A HUE16813437A HUE054159T2 HU E054159 T2 HUE054159 T2 HU E054159T2 HU E16813437 A HUE16813437 A HU E16813437A HU E16813437 A HUE16813437 A HU E16813437A HU E054159 T2 HUE054159 T2 HU E054159T2
Authority
HU
Hungary
Prior art keywords
application
hpk1 inhibitors
hpk1
inhibitors
Prior art date
Application number
HUE16813437A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Brent Sampson
Narendra Kumar B Patel
Heinz W Pauls
Sze-Wan Li
Grace Ng
Radoslaw Laufer
Yong Liu
Yunhui Lang
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of HUE054159T2 publication Critical patent/HUE054159T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE16813437A 2015-06-25 2016-06-23 HPK1 gátlók és azok alkalmazási módja HUE054159T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562184348P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
HUE054159T2 true HUE054159T2 (hu) 2021-08-30

Family

ID=57584335

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16813437A HUE054159T2 (hu) 2015-06-25 2016-06-23 HPK1 gátlók és azok alkalmazási módja

Country Status (26)

Country Link
US (3) US10501474B2 (OSRAM)
EP (1) EP3322711B1 (OSRAM)
JP (3) JP6898868B2 (OSRAM)
KR (2) KR102614872B1 (OSRAM)
CN (2) CN107922431B (OSRAM)
AU (1) AU2016282289B2 (OSRAM)
BR (2) BR112017027241B1 (OSRAM)
CY (1) CY1124489T1 (OSRAM)
DK (1) DK3322711T3 (OSRAM)
EA (1) EA035421B1 (OSRAM)
ES (1) ES2872555T3 (OSRAM)
HR (1) HRP20210895T1 (OSRAM)
HU (1) HUE054159T2 (OSRAM)
IL (2) IL283353B (OSRAM)
LT (1) LT3322711T (OSRAM)
MA (1) MA42456B1 (OSRAM)
MD (1) MD3322711T2 (OSRAM)
MX (2) MX386480B (OSRAM)
PL (1) PL3322711T3 (OSRAM)
PT (1) PT3322711T (OSRAM)
RS (1) RS61919B1 (OSRAM)
SG (1) SG10202105964RA (OSRAM)
SI (1) SI3322711T1 (OSRAM)
SM (1) SMT202100324T1 (OSRAM)
TW (1) TWI733679B (OSRAM)
WO (1) WO2016205942A1 (OSRAM)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322711B1 (en) * 2015-06-25 2021-03-10 University Health Network Hpk1 inhibitors and methods of using same
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
CN109923114B (zh) 2016-09-09 2022-11-01 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN110402248B (zh) * 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
MA48994A (fr) * 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
US10407424B2 (en) * 2017-03-30 2019-09-10 Genentech, Inc. Naphthyridines as inhibitors of HPK1
CA3074381A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2018228920A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2018228923A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
CA3070013A1 (en) 2017-07-18 2019-01-24 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN109721620B (zh) * 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
JP7167146B2 (ja) * 2017-11-06 2022-11-08 ブリストル－マイヤーズ スクイブ カンパニー Ｈｐｋ１阻害剤として有用なイソフラノン化合物
AU2019223955B2 (en) * 2018-02-20 2024-06-13 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for treating cancer
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
TW202012405A (zh) * 2018-07-24 2020-04-01 瑞士商赫孚孟拉羅股份公司 萘啶化合物及其用途
EP3826722A1 (en) 2018-07-24 2021-06-02 F. Hoffmann-La Roche AG Isoquinoline compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
EP3860980A1 (en) * 2018-10-03 2021-08-11 F. Hoffmann-La Roche AG 8-aminoisoquinoline compounds and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020120257A1 (en) 2018-12-11 2020-06-18 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
MX2021007853A (es) * 2018-12-26 2021-08-11 Janssen Pharmaceutica Nv Compuestos de tienopiridinona.
US12492194B2 (en) 2019-03-26 2025-12-09 Janssen Pharmaceutica Nv HPK1 inhibitors
MA55478A (fr) 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs bicycliques de hpk1
KR20200133188A (ko) * 2019-05-17 2020-11-26 보로노이바이오 주식회사 헤테로고리 융합 피리미딘 유도체 및 이의 용도
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
CN114127067B (zh) 2019-07-17 2024-08-23 百济神州有限公司 作为hpk1抑制剂的三环化合物及其用途
WO2021026180A1 (en) 2019-08-06 2021-02-11 Incyte Corporation Solid forms of an hpk1 inhibitor
BR112022004451A2 (pt) * 2019-09-13 2022-06-21 Nimbus Saturn Inc Antagonistas de hpk1 e usos dos mesmos
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
BR112022011115A2 (pt) * 2020-01-09 2022-08-23 Sumitomo Chemical Co Composto heterocíclico e composição de controle de artrópode nocivo, incluindo o mesmo
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
JP2023522618A (ja) * 2020-04-13 2023-05-31 ユニバーシティー ヘルス ネットワーク サイトカイン放出症候群を治療するための方法
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
KR20230019110A (ko) * 2020-05-11 2023-02-07 유니버시티 헬스 네트워크 4-아미노-5-(6-(4-메틸피페라진-1-일)-1H-벤조[D]이미다졸-2-일)티에노[2,3-b]피리딘-6(7H)-온(one)의 염 및 결정형
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
CN113845531B (zh) * 2020-06-28 2025-06-27 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
CN114599653B (zh) * 2020-09-28 2025-12-16 第一生物治疗股份有限公司 作为造血祖细胞激酶1(hpk1)抑制剂的吲唑及其使用方法
AU2021352535A1 (en) 2020-09-30 2023-06-01 Beone Medicines I Gmbh 3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof
US20230406864A1 (en) * 2020-11-09 2023-12-21 Merck Sharp & Dohme Llc 7-azole substituted 2-aminoquinazoline inhibitors of hpk1
WO2022111517A1 (zh) * 2020-11-24 2022-06-02 正大天晴药业集团股份有限公司 氘修饰的噻吩并吡啶酮化合物
CN114805330A (zh) * 2021-01-22 2022-07-29 苏州信诺维医药科技股份有限公司 Hpk1抑制剂、其制备方法、药物组合物及其应用
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors
CN114907377A (zh) * 2021-02-10 2022-08-16 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
JP2024509192A (ja) 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
WO2022188823A1 (zh) * 2021-03-10 2022-09-15 山东轩竹医药科技有限公司 三并环类hpk1抑制剂及其用途
CN116981666A (zh) * 2021-03-26 2023-10-31 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CN117597336A (zh) * 2021-04-30 2024-02-23 安大略省癌症研究所(Oicr) 作为造血祖细胞激酶1(hpk1)抑制剂的卤素取代的氨基氮杂-杂芳基化合物
JP2024517771A (ja) * 2021-04-30 2024-04-23 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） 造血前駆キナーゼ１（ｈｐｋ１）の阻害剤としての置換アミノアザヘテロアリール化合物
WO2022226667A1 (en) * 2021-04-30 2022-11-03 Ontario Institute For Cancer Research (Oicr) Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022253252A1 (en) * 2021-06-03 2022-12-08 Silexon Biotech Co., Ltd. Heterocyclic compounds useful as hpk1 inhibitors
CN115433161A (zh) * 2021-06-04 2022-12-06 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024527623A (ja) 2021-07-20 2024-07-25 アストラゼネカ・アクチエボラーグ 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤
JP2024528986A (ja) * 2021-08-03 2024-08-01 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
WO2023023942A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
WO2023057882A1 (en) * 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
EP4416146A4 (en) * 2021-10-15 2025-11-05 Lomond Therapeutics Inc 1H-PYRAZOLO[4,3-C]QUINOLINE SUBSTITUTES, THEIR PREPARATION PROCESSES AND THEIR USE
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
CN118339168A (zh) * 2021-12-17 2024-07-12 西藏海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2025500977A (ja) * 2021-12-22 2025-01-15 ユニバーシティー ヘルス ネットワーク 急性骨髄性白血病またはリンパ腫の処置
WO2023138612A1 (en) * 2022-01-19 2023-07-27 Silexon Ai Technology Co., Ltd. Heterocyclic compounds useful as hpk1 inhibitors
WO2023143384A1 (zh) * 2022-01-27 2023-08-03 四川海思科制药有限公司 一种抑制或降解hpk1激酶的化合物及其在医药中的用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN116462685B (zh) * 2022-02-08 2025-02-11 和径医药科技（上海）有限公司 杂环化合物、包含其的药物组合物及其抗肿瘤应用
US12358887B2 (en) 2022-03-17 2025-07-15 Gilead Sciences, Inc. IKAROS Zinc Finger Family degraders and uses thereof
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
CN117624187B (zh) * 2022-11-17 2025-11-04 杭州阿诺生物医药科技有限公司 一种高效的hpk1降解剂化合物及其制备方法和应用
KR102855849B1 (ko) 2022-11-25 2025-09-08 충남대학교산학협력단 이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024206869A2 (en) * 2023-03-30 2024-10-03 Board Of Regents, The University Of Texas System Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025080099A1 (ko) * 2023-10-13 2025-04-17 주식회사유한양행 7,7-다이메틸푸로[3,4-b]피리딘-5(7h)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2025096647A1 (en) * 2023-10-30 2025-05-08 Nimbus Saturn, Inc. Methods of treating tumors
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7314200A (en) * 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
DE60018782T2 (de) * 1999-10-19 2006-04-06 Merck & Co., Inc. Tyrosin kinase inhibitoren
WO2002018383A2 (en) * 2000-09-01 2002-03-07 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP2151440A4 (en) 2007-05-21 2010-10-20 Takeda Pharmaceutical Heterocyclic compound and use thereof
HUE027857T2 (en) 2008-04-11 2016-11-28 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
AU2009243811B2 (en) 2008-05-05 2014-04-10 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
CA2825028A1 (en) 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
GB201114212D0 (en) * 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
EP3322711B1 (en) 2015-06-25 2021-03-10 University Health Network Hpk1 inhibitors and methods of using same

Also Published As

Publication number Publication date
KR102740623B1 (ko) 2024-12-10
PL3322711T3 (pl) 2021-10-25
IL256250B (en) 2021-06-30
TWI733679B (zh) 2021-07-21
WO2016205942A1 (en) 2016-12-29
EA035421B1 (ru) 2020-06-11
KR20240000617A (ko) 2024-01-02
ES2872555T3 (es) 2021-11-02
HK1255833A1 (en) 2019-08-30
KR20180015255A (ko) 2018-02-12
US11059832B2 (en) 2021-07-13
US20200190104A1 (en) 2020-06-18
CA2989684A1 (en) 2016-12-29
MX2018000048A (es) 2018-06-06
US20180179221A1 (en) 2018-06-28
KR102614872B1 (ko) 2023-12-15
HRP20210895T1 (hr) 2021-08-20
PT3322711T (pt) 2021-05-13
IL283353A (en) 2021-07-29
IL256250A (en) 2018-02-28
DK3322711T3 (en) 2021-04-26
MD3322711T2 (ro) 2021-07-31
CN107922431B (zh) 2021-06-04
CN107922431A (zh) 2018-04-17
TW201718597A (zh) 2017-06-01
JP7241810B2 (ja) 2023-03-17
JP2018522858A (ja) 2018-08-16
MX386480B (es) 2025-03-18
LT3322711T (lt) 2021-05-10
BR112017027241A2 (OSRAM) 2018-08-21
JP2021138754A (ja) 2021-09-16
US10501474B2 (en) 2019-12-10
JP2023071911A (ja) 2023-05-23
BR122023006150B1 (pt) 2023-12-12
RS61919B1 (sr) 2021-06-30
IL283353B (en) 2022-09-01
US20220002313A1 (en) 2022-01-06
MA42456A (fr) 2018-05-23
SMT202100324T1 (it) 2021-07-12
CN113214287B (zh) 2023-10-20
CY1124489T1 (el) 2022-07-22
SG10202105964RA (en) 2021-07-29
EP3322711A4 (en) 2018-12-19
AU2016282289A1 (en) 2018-01-04
EP3322711B1 (en) 2021-03-10
NZ738268A (en) 2024-04-26
AU2016282289B2 (en) 2020-12-24
SI3322711T1 (sl) 2021-08-31
CN113214287A (zh) 2021-08-06
MX2021011435A (es) 2021-10-13
JP6898868B2 (ja) 2021-07-07
BR112017027241B1 (pt) 2023-09-26
EP3322711A1 (en) 2018-05-23
MA42456B1 (fr) 2021-06-30
EA201890059A1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
HUE054159T2 (hu) HPK1 gátlók és azok alkalmazási módja
IL280863A (en) Autotaxin inhibitors and uses thereof
IL259766B (en) Relocalization systems and methods
IL256369A (en) Novel crispr enzymes and systems
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
HUE055233T2 (hu) Az EGFR gátló és annak elkészítése és alkalmazása
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
HUE045216T2 (hu) Anti-CD79B antitestek és alkalmazási eljárások
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
HUE054347T2 (hu) MK2 inhibitorok és azok alkalmazásai
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
HUE052373T2 (hu) Szubsztituált krománok és alkalmazási eljárások
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
HUE059925T2 (hu) Módosított aminoacil-tRNS-szintetáz és alkalmazása
CL2018000700A1 (es) Sililfenoxiheterociclos trisustituidos y análogos
EP3341387A4 (en) SIALYL TRANSFERASE INHIBITORS AND USES THEREOF
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
HUE046509T2 (hu) Új vegyület és eljárás
EP3350489A4 (en) VALVE AND COUPLING
HUE063120T2 (hu) LRRC33-inhibitorok és alkalmazásuk
FI20155621A7 (fi) Menetelmä ja tuote
DK3262182T3 (da) Modificeret creatinase